Literature DB >> 19228439

Congenital adrenal hyperplasia because of 21-hydroxylase deficiency. A genetic disorder of interest to obstetricians and gynecologists.

Eftihios Trakakis1, Constantine Loghis, Demetrios Kassanos.   

Abstract

Congenital adrenal hyperplasia (CAH) due to deficiency of the enzyme 21-hydroxylase (21-OH), is distinguished in its classical and nonclassical form and is one of the most common autosomal recessive inherited diseases in humans. The classical form appears between 1:5000 and 1:15000 among the live neonates of North America and Europe, whereas the nonclassical form occurs in approximately 0.2% of the general white populations. Three alleles are associated with the 21-OH locus and can be combined in various ways to individuals who are either unaffected, heterozygote carriers, or affected with the classical or nonclassical disease. Variable signs and symptoms of hyperandrogenism are common to both types of the disorder. In women with CAH, hyperandrogenism may be present, extending from virilization of external genitalia and salt-wasting in classical (C)-CAH cases, to menstrual irregularity, obesity, short stature, infertility or subfertility and skin disorders such as hirsutism, in nonclassical (NC)-CAH cases. These clinical characteristics of NC-CAH cases do not differ unmarkedly from those shown in patients with polycystic ovary syndrome, idiopathic hirsutism, or hyperinsulinemia. The significant advances in molecular biology and gene analysis over the past 2 decades have led to the development of novel sensitive methods of DNA analysis and study, including polymerase chain reaction and Southern blot analysis. Thus it has been revealed that the 21-OH gene (CYP21A2) and its nonfunctional pseudogene (CYP21A1P) are located on chromosome 6 (6p21.3), sharing a high homology of about 98%. Inactivating mutations occur as complete gene deletions, large gene conversions and pseudogene-derived mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228439     DOI: 10.1097/OGX.0b013e318193301b

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  7 in total

1.  Molecular diagnosis of Chinese patients with 21-hydroxylase deficiency and analysis of genotype-phenotype correlations.

Authors:  Bo Zhang; Lin Lu; Zhaolin Lu
Journal:  J Int Med Res       Date:  2017-02-02       Impact factor: 1.671

Review 2.  The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway.

Authors:  Aihua Wu; Martin Wolley; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2019-02-05       Impact factor: 3.012

3.  Physical, social and societal functioning of children with congenital adrenal hyperplasia (CAH) and their parents, in a Dutch population.

Authors:  Sarita A Sanches; Therese A Wiegers; Barto J Otten; Hedi L Claahsen-van der Grinten
Journal:  Int J Pediatr Endocrinol       Date:  2012-02-02

Review 4.  Molecular Diagnosis of Steroid 21-Hydroxylase Deficiency: A Practical Approach.

Authors:  María Arriba; Begoña Ezquieta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

5.  A Retrospective Analysis of the Growth Pattern in Patients with Salt-wasting 21-Hydroxylase Deficiency.

Authors:  Atsuko Kawano; Hitoshi Kohno; Kenichi Miyako
Journal:  Clin Pediatr Endocrinol       Date:  2014-04-22

6.  Functional and Structural Consequences of Nine CYP21A2 Mutations Ranging from Very Mild to Severe Effects.

Authors:  Débora de Paula Michelatto; Leif Karlsson; Ana Letícia Gori Lusa; Camila D'Almeida Mgnani Silva; Linus Joakim Östberg; Bengt Persson; Gil Guerra-Júnior; Sofia Helena Valente de Lemos-Marini; Michela Barbaro; Maricilda Palandi de Mello; Svetlana Lajic
Journal:  Int J Endocrinol       Date:  2016-09-19       Impact factor: 3.257

Review 7.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.